Iovance Biotherapeutics, Inc. (IOVA) shareholders
Close on Nov 17, 2026Market cap $3.41BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 33,366,587 | 7.50% | 13G (passive) amendment | Jun 30, 2026 |
| Wayne P. Rothbaum Joint filing with Quogue Capital LLC (11.60%) | 30,000,000 | 11.60% | 13D (active) amendment | Feb 20, 2024 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (7.30%), Perceptive Life Sciences Master Fund, Ltd. (7.30%) | 22,112,266 | 7.30% | 13G (passive) amendment | Dec 31, 2024 |
| Mark H. Rachesky, M.D Joint filing with Mhr Advisors LLC (7.80%), Mhrc LLC (7.80%) and 3 more | 20,083,951 | 7.80% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IOVA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 36,957,681 | 8.16% | $153.74M | +5,877,176 | 0.00% |
| Mhr Fund Management LLC | 28,967,103 | 6.39% | $120.50M | – | 6.28% |
| State Street Corp | 24,478,268 | 5.40% | $101.83M | +7,030,160 | 0.00% |
| Two Sigma Investments, LP | 19,010,697 | 4.20% | $79.08M | +5,323,264 | 0.06% |
| Vanguard Capital Management LLC | 18,204,248 | 4.02% | $75.73M | +1,586,511 | 0.00% |
| Vanguard Portfolio Management LLC | 14,388,999 | 3.18% | $59.86M | +2,688,155 | 0.00% |
| Geode Capital Management, LLC | 10,324,826 | 2.28% | $42.96M | +1,752,228 | 0.00% |
| Millennium Management LLC | 8,525,919 | 1.88% | $35.47M | −888,373 | 0.01% |
| Dimensional Fund Advisors LP | 6,460,449 | 1.43% | $26.88M | +3,814,747 | 0.00% |
| Palo Alto Investors LP | 5,296,209 | 1.17% | $22.03M | −1,053,354 | 3.04% |
| Goldman Sachs Group Inc | 5,096,334 | 1.13% | $21.20M | −3,663,726 | 0.00% |
| Nuveen, LLC | 4,997,112 | 1.10% | $20.79M | +1,332,834 | 0.00% |
| Bank Of America Corp /De/ | 4,993,584 | 1.10% | $20.77M | −3,496,535 | 0.00% |
| Morgan Stanley | 4,986,461 | 1.10% | $20.74M | −1,214,821 | 0.00% |
| Jupiter Asset Management Ltd | 4,535,080 | 1.00% | $18.87M | New | 0.09% |
| Jane Street Group, LLC | 4,393,853 | 0.97% | $18.28M | +219,967 | 0.00% |
| Northern Trust Corp | 4,154,200 | 0.92% | $17.28M | +1,278,674 | 0.00% |
| Aqr Capital Management LLC | 3,869,584 | 0.85% | $16.10M | +3,245,416 | 0.01% |
| Wells Fargo & Company/Mn | 3,246,537 | 0.72% | $13.51M | +1,175,013 | 0.00% |
| Charles Schwab Investment Management Inc | 3,219,656 | 0.71% | $13.39M | +435,926 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 292 | 287M | 63.3% | 45 / 132 | 65 / 35 | 53M | 35M |
| Q1 2026 | 286 | 269M | 59.4% | 64 / 122 | 58 / 38 | 73M | 38M |
| Q4 2025 | 263 | 262M | 57.8% | 51 / 104 | 63 / 36 | 61M | 13M |
| Q3 2025 | 253 | 214M | 47.3% | 41 / 83 | 77 / 40 | 27M | 36M |
| Q2 2025 | 255 | 223M | 49.2% | 40 / 93 | 72 / 84 | 50M | 68M |
| Q1 2025 | 302 | 240M | 53.0% | 57 / 101 | 93 / 54 | 39M | 39M |
| Q4 2024 | 301 | 242M | 53.3% | 57 / 101 | 86 / 36 | 28M | 22M |
| Q3 2024 | 286 | 237M | 52.4% | 40 / 107 | 84 / 46 | 52M | 29M |
| Q2 2024 | 295 | 236M | 52.1% | 67 / 114 | 81 / 41 | 39M | 28M |
| Q1 2024 | 273 | 227M | 50.1% | 70 / 91 | 82 / 33 | 48M | 35M |
| Q4 2023 | 236 | 214M | 47.2% | 48 / 87 | 70 / 36 | 27M | 26M |
| Q3 2023 | 227 | 214M | 47.1% | 41 / 107 | 52 / 31 | 45M | 31M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
185 funds held IOVA in Q2 2026, 69% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IOVA | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 14,493,812 | 3.20% | $60.29M | 0.56% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 13,485,679 | 2.98% | $56.10M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 10,352,918 | 2.29% | $43.07M | 0.05% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 4,858,231 | 1.07% | $20.21M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 4,351,328 | 0.96% | $17.71M | 0.05% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 4,305,078 | 0.95% | $17.91M | 0.02% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 3,723,294 | 0.82% | $15.49M | 0.11% | Jun 30, 2026 |
| Vanguard Small-Cap Value Index Fund | 3,081,166 | 0.68% | $12.82M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 2,737,376 | 0.60% | $11.39M | 0.13% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 2,707,990 | 0.60% | $11.02M | 0.27% | Jul 31, 2026 |
| Vanguard Strategic Equity Fund | 2,018,606 | 0.45% | $8.40M | 0.07% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 1,733,813 | 0.38% | $7.11M | 0.04% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 1,727,875 | 0.38% | $7.08M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,615,534 | 0.36% | $6.62M | 0.03% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,439,842 | 0.32% | $5.99M | 0.05% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Frederick G. Vogt | Interim CEO & General Counsel, Director | 604,144 | 0.13% | Nov 13, 2026 |
| Daniel Gordon Kirby | Chief Commercial Officer | 160,576 | 0.04% | Nov 12, 2026 |
| Corleen M. Roche | Chief Financial Officer | 35,946 | 0.01% | Nov 10, 2026 |
| Noah Berkowitz | Chief Medical Officer | – | – | Oct 2, 2026 |
| Raj K. Puri | Chief Regulatory Officer | 260,842 | 0.06% | Sep 10, 2026 |
| Igor Bilinsky | Chief Operating Officer | 142,074 | 0.03% | Sep 10, 2026 |
| Finckenstein Friedrich Graf | Chief Medical Officer | 144,087 | 0.03% | Jun 9, 2026 |
| Matthew W. Rosinack | SVP, Finance (Int. PFO & PAO) | 89,129 | 0.02% | Jul 10, 2025 |
| Jean-Marc Bellemin | Chief Financial Officer | 64,993 | 0.01% | Jun 4, 2025 |
| Michael Weiser | Director | 133,303 | 0.03% | Jun 18, 2026 |
| Iain D. Dukes | Director | 54,000 | 0.01% | Jun 18, 2026 |
| Ryan D. Maynard | Director | 57,500 | 0.01% | Jun 18, 2026 |
| Athena Countouriotis | Director | – | – | Jun 18, 2026 |
| Wendy L. Yarno | Director | – | – | Jun 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Frederick G. Vogt Interim CEO & General Counsel, Director | Nov 11, 2026 | Tax withholding | −191,303 | $8.09 | $1.55M | 604,144 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Nov 11, 2026 | Option exercise | +200,000 | $7.55 | $1.51M | 795,447 |
| Daniel Gordon Kirby Chief Commercial Officer | Nov 10, 2026 | Tax withholding | −3,935 | $8.08 | $31.79K | 160,576 |
| Daniel Gordon Kirby Chief Commercial Officer | Nov 10, 2026 | Option exercise | +10,000 | – | – | 164,511 |
| Corleen M. Roche Chief Financial Officer | Nov 6, 2026 | Tax withholding | −5,311 | $8.04 | $42.70K | 35,946 |
| Corleen M. Roche Chief Financial Officer | Nov 6, 2026 | Option exercise | +12,500 | – | – | 41,257 |
| Raj K. Puri Chief Regulatory Officer | Sep 8, 2026 | Option exercise | +9,766 | – | – | 260,842 |
| Raj K. Puri Chief Regulatory Officer | Sep 8, 2026 | Tax withholding | −4,478 | $8.70 | $38.96K | 256,364 |
| Igor Bilinsky Chief Operating Officer | Sep 8, 2026 | Tax withholding | −3,976 | $8.70 | $34.59K | 142,074 |
| Igor Bilinsky Chief Operating Officer | Sep 8, 2026 | Option exercise | +7,813 | – | – | 146,050 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Sep 8, 2026 | Tax withholding | −6,638 | $8.70 | $57.75K | 595,447 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Sep 8, 2026 | Option exercise | +15,626 | – | – | 602,085 |
| Igor Bilinsky Chief Operating Officer | Sep 1, 2026 | Tax withholding | −4,472 | $8.28 | $37.03K | 138,237 |
| Igor Bilinsky Chief Operating Officer | Sep 1, 2026 | Option exercise | +8,789 | – | – | 142,709 |
| Raj K. Puri Chief Regulatory Officer | Sep 1, 2026 | Tax withholding | −2,508 | $8.28 | $20.77K | 251,076 |
| Raj K. Puri Chief Regulatory Officer | Sep 1, 2026 | Option exercise | +5,470 | – | – | 253,584 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Sep 1, 2026 | Tax withholding | −17,702 | $8.28 | $146.57K | 586,459 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Sep 1, 2026 | Option exercise | +41,669 | – | – | 604,161 |
| Daniel Gordon Kirby Chief Commercial Officer | Aug 10, 2026 | Tax withholding | −2,436 | $6.40 | $15.59K | 154,511 |
| Daniel Gordon Kirby Chief Commercial Officer | Aug 10, 2026 | Option exercise | +10,001 | – | – | 156,947 |
| Corleen M. Roche Chief Financial Officer | Aug 6, 2026 | Option exercise | +49,995 | – | – | 49,995 |
| Corleen M. Roche Chief Financial Officer | Aug 6, 2026 | Tax withholding | −21,238 | $6.21 | $131.89K | 28,757 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Jun 5, 2026 | Tax withholding | −6,638 | $4.23 | $28.08K | 562,492 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Jun 5, 2026 | Option exercise | +15,625 | – | – | 569,130 |
| Finckenstein Friedrich Graf Chief Medical Officer | Jun 5, 2026 | Option exercise | +7,813 | – | – | 144,087 |
| Finckenstein Friedrich Graf Chief Medical Officer | Jun 5, 2026 | Tax withholding | −3,976 | $4.23 | $16.82K | 140,111 |
| Igor Bilinsky Chief Operating Officer | Jun 5, 2026 | Option exercise | +7,813 | – | – | 137,896 |
| Igor Bilinsky Chief Operating Officer | Jun 5, 2026 | Tax withholding | −3,976 | $4.23 | $16.82K | 133,920 |
| Raj K. Puri Chief Regulatory Officer | Jun 5, 2026 | Tax withholding | −3,843 | $4.23 | $16.26K | 248,114 |
| Raj K. Puri Chief Regulatory Officer | Jun 5, 2026 | Option exercise | +9,766 | – | – | 251,957 |
| Raj K. Puri Chief Regulatory Officer | Jun 1, 2026 | Tax withholding | −2,508 | $3.96 | $9.93K | 242,191 |
| Raj K. Puri Chief Regulatory Officer | Jun 1, 2026 | Option exercise | +5,469 | – | – | 244,699 |
| Igor Bilinsky Chief Operating Officer | Jun 1, 2026 | Option exercise | +8,790 | – | – | 134,556 |
| Igor Bilinsky Chief Operating Officer | Jun 1, 2026 | Tax withholding | −4,473 | $3.96 | $17.71K | 130,083 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Jun 1, 2026 | Option exercise | +41,668 | – | – | 571,206 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Jun 1, 2026 | Tax withholding | −17,701 | $3.96 | $70.10K | 553,505 |
| Finckenstein Friedrich Graf Chief Medical Officer | Jun 1, 2026 | Tax withholding | −4,473 | $3.96 | $17.71K | 136,274 |
| Finckenstein Friedrich Graf Chief Medical Officer | Jun 1, 2026 | Option exercise | +8,790 | – | – | 140,747 |
| Daniel Gordon Kirby Chief Commercial Officer | May 11, 2026 | Tax withholding | −2,435 | $3.70 | $9.01K | 146,946 |
| Daniel Gordon Kirby Chief Commercial Officer | May 11, 2026 | Option exercise | +10,000 | – | – | 149,381 |
| Raj K. Puri Chief Regulatory Officer | Mar 5, 2026 | Tax withholding | −18,360 | $4.58 | $84.09K | 239,230 |
| Raj K. Puri Chief Regulatory Officer | Mar 5, 2026 | Option exercise | +39,059 | – | – | 257,590 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Mar 5, 2026 | Tax withholding | −26,755 | $4.58 | $122.54K | 529,538 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Mar 5, 2026 | Option exercise | +62,493 | – | – | 556,293 |
| Igor Bilinsky Chief Operating Officer | Mar 5, 2026 | Tax withholding | −16,628 | $4.58 | $76.16K | 125,766 |
| Igor Bilinsky Chief Operating Officer | Mar 5, 2026 | Option exercise | +31,246 | – | – | 142,394 |
| Finckenstein Friedrich Graf Chief Medical Officer | Mar 5, 2026 | Tax withholding | −16,520 | $4.58 | $75.66K | 131,957 |
| Finckenstein Friedrich Graf Chief Medical Officer | Mar 5, 2026 | Option exercise | +31,246 | – | – | 148,477 |
| Igor Bilinsky Chief Operating Officer | Mar 2, 2026 | Tax withholding | −6,903 | $3.79 | $26.16K | 111,148 |
| Igor Bilinsky Chief Operating Officer | Mar 2, 2026 | Option exercise | +12,307 | – | – | 118,051 |
| Finckenstein Friedrich Graf Chief Medical Officer | Mar 2, 2026 | Option exercise | +12,697 | – | – | 124,353 |
| Finckenstein Friedrich Graf Chief Medical Officer | Mar 2, 2026 | Tax withholding | −7,122 | $3.79 | $26.99K | 117,231 |
| Raj K. Puri Chief Regulatory Officer | Mar 2, 2026 | Tax withholding | −2,798 | $3.79 | $10.60K | 218,531 |
| Raj K. Puri Chief Regulatory Officer | Mar 2, 2026 | Option exercise | +5,470 | – | – | 221,329 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Mar 2, 2026 | Tax withholding | −22,809 | $3.79 | $86.45K | 493,800 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Mar 2, 2026 | Option exercise | +52,087 | – | – | 516,609 |
| Daniel Gordon Kirby Chief Commercial Officer | Feb 24, 2026 | Tax withholding | −34,165 | $3.78 | $129.14K | 139,381 |
| Daniel Gordon Kirby Chief Commercial Officer | Feb 24, 2026 | Option exercise | +120,000 | – | – | 173,546 |
| Daniel Gordon Kirby Chief Commercial Officer | Feb 10, 2026 | Tax withholding | −16,450 | $2.60 | $42.77K | 53,546 |
| Daniel Gordon Kirby Chief Commercial Officer | Feb 10, 2026 | Option exercise | +39,996 | – | – | 69,996 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Iovance Biotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 575,562 shares on Oct 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ryan D. Maynard Director | Nov 12, 2024 | 50,000 | $503.10K | Nov 12, 2024 | Stock Option (right to buy) |
See a number that looks wrong?